<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02983448</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-7147</org_study_id>
    <nct_id>NCT02983448</nct_id>
  </id_info>
  <brief_title>Noninvasive Neuromodulation to Reserve Diastolic Dysfunction</brief_title>
  <acronym>NERDD</acronym>
  <official_title>Noninvasive Neuromodulation to Reserve Diastolic Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oklahoma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Oklahoma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 2x2 cross over pilot study using low level transcutaneous vagus nerve stimulation
      (LLTS) to reverse diastolic dysfunction in patients with diastolic dysfunction. All patients
      will receive 2 separate, 1-hour sequences, at least 1 day apart, of active and sham LLTS, but
      the sequence will be randomized. Patients will be randomly assigned (1:1) to active/sham or
      sham/active LLTS. LLTS will be performed using a transcutaneous electrical nerve stimulation
      (TENS) device with electrodes attached to the tragus of the ear, which is innervated by
      auricular branch of the vagus nerve. Echocardiography will be performed after 30 minutes of
      LLTS or sham stimulation to assess diastolic function. Five-minute ECGs will be obtained for
      HRV analysis every 15 minutes of stimulation (total of 4 recordings).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2016</start_date>
  <completion_date type="Actual">April 2018</completion_date>
  <primary_completion_date type="Actual">March 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Echocardiographic markers of diastolic dysfunction</measure>
    <time_frame>after 1 hour of stimulation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>heart rate variability measures</measure>
    <time_frame>after 1 hour of stimulation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Heart Failure, Diastolic</condition>
  <arm_group>
    <arm_group_label>Sham stimulation first</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sham stimulation delivered at the earlobe (devoid of vagal innervation) is given on first session.
Transcutaneous vagus nerve stimulation delivered at the tragus (vagal innervation) is given on second session.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active stimulation first</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Transcutaneous vagus nerve stimulation delivered at the earlobe (vagal innervation) is given on first session.
Sham stimulation delivered at the tragus (devoid of vagal innervation) is given on second session.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>transcutaneous vagus nerve stimulation</intervention_name>
    <description>All patients will receive both active and sham transcutaneous vagus nerve stimulation, with the order being randomized</description>
    <arm_group_label>Sham stimulation first</arm_group_label>
    <arm_group_label>Active stimulation first</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female patients older than 18 year old

          2. Evidence of diastolic dysfunction on echocardiogram within 24 months of study
             enrollment

        Exclusion Criteria:

          1. Left ventricular dysfunction (Left ventricular ejection fraction &lt;40%)

          2. Significant valvular disorder (i.e., prosthetic valve or hemodynamically relevant
             valvular diseases)

          3. Recent (&lt;6 months) stroke or myocardial infarction

          4. Severe heart failure (NYHA class III or IV)

          5. Recurrent vaso-vagal syncopal episodes

          6. Unilateral or bilateral vagotomy

          7. Pregnancy or breast feeding

          8. Sick sinus syndrome (without a pacemaker), 2nd or 3rd degree AV block, bifascicular
             block or prolonged (PR&gt;300ms) 1st degree AV block
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2016</study_first_submitted>
  <study_first_submitted_qc>December 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2016</study_first_posted>
  <last_update_submitted>May 25, 2018</last_update_submitted>
  <last_update_submitted_qc>May 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Oklahoma</investigator_affiliation>
    <investigator_full_name>Stavros Stavrakis</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Failure, Diastolic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

